BOSTON & MONTREAL, January 31, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product ...
BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...
BALTIMORE, Jan. 31, 2025 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation (UCF), the official foundation of the American Urological Association (AUA), ...
Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback